View Current MeetingsMeeting Program
 |
To view program in "24 hour" time (international) click here. |
| Friday, January 8 | ||
|---|---|---|
| 3:00 - 7:30 PM | Registration | Matterhorn Foyer |
| 6:30 - 7:30 PM | Refreshments | Matterhorn Foyer |
| 7:30 - 8:30 PM |
Keynote Address Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
Napoleone Ferrara,
Genentech, Inc., USA
The Avastin Story: Challenges and Lessons |
||
| Saturday, January 9 | ||
| 7:00 - 8:00 AM | Breakfast | Schneitter's |
| 8:00 - 11:00 AM |
Antibody Discovery and Engineering Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
Matthew Sleeman,
MedImmune, USA
Antibody Structure Function Relationships |
||
|
Tillman U. Gerngross,
Dartmouth College and CEO and Co-founder of Adimab, USA
Adimab’s Novel Human Antibody Discovery Platform: A New Benchmark for Antibody Discovery Technologies |
||
|
John R. Desjarlais,
Xencor, USA
Creating Novel and Enhanced Antibody Therapeutics through Fc Engineering |
||
|
James A. Van Deventer,
California Institute of Technology, USA
Short Talk: Antibody Fragment Engineering With Non-Canonical Amino Acids |
||
| 11:00 AM- | On Own for Lunch and Recreation | |
| 9:20 - 9:40 AM | Coffee Break | Matterhorn Foyer |
| 4:30 - 5:00 PM | Coffee Available | Matterhorn Foyer |
| 5:00 - 7:00 PM |
Protein and Peptide Engineering Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
W. David Shen,
Merck & Co., Inc., USA
From Mammalian Cell Display to Cross-Species Display of Antibodies |
||
|
Clark Pan,
Genzyme Corporation, USA
Carbohydrate Engineering of Acid alpha-Glucosidase for Treatment of Pompe Disease |
||
|
David V. Liu,
Massachusetts Institute of Technology, USA
Short Talk: Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells |
||
| 7:00 - 8:00 PM | Social Hour w/ Lite Bites | Grindelwald/Davos |
| Sunday, January 10 | ||
| 7:00 - 8:00 AM | Breakfast | Schneitter's |
| 8:00 - 11:00 AM |
Next Generation Protein-Based Biopharmaceuticals Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
Volker Schellenberger,
Amunix Inc., USA
Protein Pharmaceuticals Comprising an XTEN Half-Life Extension Module |
||
|
Richard J.M. Ross,
University of Sheffield, UK
Hormone/Hormone Receptor Fusion Proteins for Improving the Pharmacokinetic/Pharmacodynamic Properties of Hormone Replacement Therapies |
||
|
Peter D. Senter,
Seattle Genetics Inc., USA
Antibody-Drug Conjugates for Cancer Therapy |
||
|
Chengbin Wu,
Abbott Bioresearch Center, USA
Protein Engineering of DVD-Ig: Focusing on Pharmacokinetics, Manufacturing, and Preformulation Studies |
||
|
Bernd J. Wranik,
Genentech, USA
Short Talk: LUZ-Y: An Engineered Antibody Format for the Production of One-Armed and Bispecific Antibodies in Mammalian (CHO) Cells |
||
| 9:20 - 9:40 AM | Coffee Break | Matterhorn Foyer |
| 11:00 AM- 1:00 PM | Poster Setup | Grindelwald/Davos |
| 11:00 AM- | On Own for Lunch and Recreation | |
| 1:00 - 10:00 PM | Poster Viewing | Grindelwald/Davos |
| 4:30 - 5:00 PM | Coffee Available | Matterhorn Foyer |
| 5:00 - 7:00 PM |
Nucleic Acid-Based Biopharmaceuticals Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
James M. Wilson,
University of Pennsylvania, USA
Gene Therapy: Lessons Learned and Opportunities for the Future |
||
|
C. Frank Bennett,
ISIS Pharmaceuticals, Inc., USA
Progress in Antisense Therapeutics |
||
|
Dinah Sah,
Alnylam Pharmaceuticals Inc., USA
Development of RNAi Therapeutics |
||
|
Pengbo Zhou,
Weill Cornell Medical College, USA
Short Talk: Integration of RNAi and Protein Knockout Technology for Efficient Eradication of Cellular Proteins |
||
| 7:00 - 8:00 PM | Social Hour w/ Lite Bites | Grindelwald/Davos |
| 7:30 - 10:00 PM |
Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Grindelwald/Davos |
| Monday, January 11 | ||
| 7:00 - 8:00 AM | Breakfast | Schneitter's |
| 8:00 - 11:00 AM |
Cancer and Cancer Supportive Care Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
Michael Reiss,
Robert Wood Johnson Medical School, USA
TGF-beta as a New Cancer Therapy Target |
||
|
Elisabeth G.E. de Vries,
Universitair Medisch Centrum Groningen, The Netherlands
Use of Zirconium-89 Labeled Antibodies for Tumor Imaging: Possible Applications for Guiding Targeted Tumor Therapy |
||
|
Patrick A. Baeuerle,
Micromet, Inc., USA
Cancer Therapy by T Cell-Engaging BiTE Antibodies |
||
|
Antonio Gualberto,
Pfizer Oncology, USA
Development of Figitumumab (CP-751,871), a Fully Human Monoclonal Antibody against the IGF-1R |
||
|
John C. Zwaagstra,
Biotechnology Research Institute NRCC, Canada
Short Talk: Design and Efficacy of Single-Chain Traps Targeting Ligands of the Transforming Growth Factor-beta (TGF-beta) Family: The New Generation of Cancer Therapeutics/Diagnostics |
||
| 9:20 - 9:40 AM | Coffee Break | Matterhorn Foyer |
| 11:00 AM- | On Own for Lunch and Recreation | |
| 1:00 - 10:00 PM | Poster Viewing | Grindelwald/Davos |
| 4:30 - 5:00 PM | Coffee Available | Matterhorn Foyer |
| 5:00 - 7:00 PM |
Immune-Mediated Diseases/Transplant Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
C. Randal Mills,
Osiris Therapeutics, Inc., USA
Mesenchymal Stem Cells for Treatment of GVHD |
||
|
Alasdair Coles,
University of Cambridge, UK
Anti-CD52 Antibodies for the Treatment of Multiple Sclerosis |
||
|
Kristine Kikly,
Eli Lilly and Company, USA
Anti-BAFF for the Treatment of Rheumatoid Arthritis |
||
| 7:00 - 8:00 PM | Social Hour w/ Lite Bites | Grindelwald/Davos |
| 7:30 - 10:00 PM |
Poster Session Viewing Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Grindelwald/Davos |
| Tuesday, January 12 | ||
| 7:00 - 8:00 AM | Breakfast | Schneitter's |
| 8:00 - 11:00 AM |
Diabetes Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
Bart Keymeulen,
Vrije Universiteit Brussel, Belgium
Preservation of Beta Cell Function in Human Type 1 Diabetes |
||
|
Sushil G. Rane,
National Institutes of Health, USA
Protection from Obesity and Diabetes by Blockade of TGF-beta/Smad3 Signaling |
||
|
Alexei Kharitonenkov,
Eli Lilly and Company, USA
FGF-21 and its Novel Variants to Treat Metabolic Disorders |
||
|
Lucienne Chatenoud,
INSERM, Hopital Necker, France
Restoration of Self Tolerance in Autoimmune Diabetes |
||
|
Biju Parekkadan,
Massachusetts General Hospital, Harvard Medical School, USA
Short Talk: Natural Therapeutics Derived from the Bone Marrow Stroma |
||
| 9:20 - 9:40 AM | Coffee Break | Matterhorn Foyer |
| 11:00 AM- | On Own for Lunch and Recreation | |
| 4:30 - 5:00 PM | Coffee Available | Matterhorn Foyer |
| 5:00 - 7:00 PM |
Metabolic and Neurological Disorders Registered attendees for this meeting can view Abstracts for this session starting on 12/08/2009 |
Matterhorn Ballroom |
|
Ronald B. DeMattos,
Lilly Research Laboratories, USA
Abeta Immunotherapy: The Development of Compound Specific Biomarkers to Aid the Translation of Preclinical to Clinical Studies |
||
|
Mike Ominsky,
Amgen Inc., USA
OPG/RANKL and Sclerostin; Physiological Regulators of Bone Density; Targets for the Treatment of Bone Loss Indications |
||
|
Marco A. Passini,
Genzyme Corporation, USA
Gene and Antisense Oligonucleotide Therapies for Spinal Muscular Atrophy |
||
|
John Chaddock,
Syntaxin Ltd, UK
Short Talk: Clostridial Endopeptidases - A Novel Platform for Therapeutic Proteins |
||
| 7:00 - 8:00 PM | Social Hour w/ Lite Bites | Grindelwald/Davos |
| 8:00 - 11:00 PM | Entertainment | Grindelwald/Davos |
| Wednesday, January 13 | ||
| Departure | ||
| *=Session Chair †=Speaker invited, not yet responded. | ||
Keystone Symposia would like to thank the sponsors of this meeting for their generous support:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
|
|
|
|
|
|
|
|
Amunix Inc. |
MedImmune |
|
Merck Vaccine Division |
Regeneron Pharmaceuticals, Inc. |
|
Seattle Genetics, Inc. |
These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.
Click here to view all of the donors who support the Directors' Fund.
We gratefully acknowledge the organizations that provide Keystone Symposia with additional support, such as marketing and advertising...
Click here to view these companies